Vi-CRM 197 as a new conjugate vaccine against Salmonella Typhi.

[1]  J. Clemens,et al.  Population impact of Vi capsular polysaccharide vaccine , 2010, Expert review of vaccines.

[2]  A. Donner,et al.  A cluster-randomized effectiveness trial of Vi typhoid vaccine in India. , 2009, The New England journal of medicine.

[3]  S. Szu,et al.  Polysaccharide-Based Conjugate Vaccines for Enteric Bacterial Infections: Typhoid Fever, Nontyphoidal Salmonellosis and Escherichia coli O157:H7 , 2009 .

[4]  C. Czerkinsky,et al.  Physical and Chemical Characterization and Immunologic Properties of Salmonella enterica Serovar Typhi Capsular Polysaccharide-Diphtheria Toxoid Conjugates , 2009, Clinical and Vaccine Immunology.

[5]  G. Keating,et al.  Pneumococcal Polysaccharide Protein D-Conjugate Vaccine (Synflorix™; PHiD-CV) , 2009, Paediatric drugs.

[6]  J. Clemens,et al.  Typhoid vaccination: the Asian experience , 2008, Expert review of vaccines.

[7]  Organización Mundial de la Salud.  Typhoid vaccines: WHO position paper. , 2008, Releve epidemiologique hebdomadaire.

[8]  J. Langley,et al.  Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. , 2008, JAMA.

[9]  L. Leibovici,et al.  Typhoid fever vaccines: systematic review and meta-analysis of randomised controlled trials. , 2007, Vaccine.

[10]  J. Vliegenthart.  Carbohydrate based vaccines , 2006, FEBS letters.

[11]  S. Clare,et al.  Evaluation of a novel Vi conjugate vaccine in a murine model of salmonellosis. , 2006, Vaccine.

[12]  D. Favre,et al.  Vaccines against typhoid fever. , 2006, Vaccine.

[13]  Lai-Xi Wang.  Carbohydrate-based vaccines against HIV/AIDS , 2006 .

[14]  C. E. Taylor,et al.  Carbohydrate Moieties as Vaccine Candidates , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  Christopher Jones,et al.  Vaccines based on the cell surface carbohydrates of pathogenic bacteria. , 2005, Anais da Academia Brasileira de Ciencias.

[16]  A. Naheed,et al.  Bacteremic Typhoid Fever in Children in an Urban Slum, Bangladesh , 2005, Emerging infectious diseases.

[17]  J. Shiloach,et al.  Effect of Dosage on Immunogenicity of a Vi Conjugate Vaccine Injected Twice into 2- to 5-Year-Old Vietnamese Children , 2004, Infection and Immunity.

[18]  J. Crump,et al.  The global burden of typhoid fever. , 2004, Bulletin of the World Health Organization.

[19]  Chao-Ming Tsai,et al.  Quantification of O-acetyl, N-acetyl and phosphate groups and determination of the extent of O-acetylation in bacterial vaccine polysaccharides by high-performance anion-exchange chromatography with conductivity detection (HPAEC-CD). , 2004, Vaccine.

[20]  A. Finn.  Bacterial polysaccharide-protein conjugate vaccines. , 2004, British medical bulletin.

[21]  D. Isaacs,et al.  Carbohydrate-protein conjugate vaccines. , 2003, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[22]  P. Talaga,et al.  Development of a high-performance anion-exchange chromatography with pulsed-amperometric detection based quantification assay for pneumococcal polysaccharides and conjugates. , 2002, Vaccine.

[23]  R. Black,et al.  Typhoid fever in Bangladesh: implications for vaccination policy. , 2001, The Pediatric infectious disease journal.

[24]  J. Shiloach,et al.  The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. , 2001, The New England journal of medicine.

[25]  N. Ravenscroft,et al.  Development of a new method for the quantitative analysis of the extracellular polysaccharide of Neisseria meningitidis serogroup A by use of high-performance anion-exchange chromatography with pulsed-amperometric detection. , 2001, Vaccine.

[26]  R. Tauxe,et al.  Laboratory-based surveillance of Salmonella serotype Typhi infections in the United States: antimicrobial resistance on the rise. , 2000, JAMA.

[27]  D. D. Trach,et al.  The epidemiology of typhoid fever in the Dong Thap Province, Mekong Delta region of Vietnam. , 2000, The American journal of tropical medicine and hygiene.

[28]  X Lemercinier,et al.  Use and validation of an NMR test for the identity and O-acetyl content of the Salmonella typhi Vi capsular polysaccharide vaccine. , 2000, Biologicals : journal of the International Association of Biological Standardization.

[29]  J. Lau,et al.  Vaccines for preventing typhoid fever , 2018, The Cochrane database of systematic reviews.

[30]  S. Black,et al.  Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers. , 1999, The Pediatric infectious disease journal.

[31]  B. Singh,et al.  Typhoid fever in children aged less than 5 years , 1999, The Lancet.

[32]  S. Szu,et al.  Bacterial polysaccharide–protein conjugate vaccines , 1999 .

[33]  R. Steele.  Safety and Immunogenicity of Heptavalent Pneumococcal Vaccine Conjugated to CRM197 in United States Infants , 1998, Clinical pediatrics.

[34]  M. Rennels,et al.  Safety and Immunogenicity of Heptavalent Pneumococcal Vaccine Conjugated to CRM197 in United States Infants , 1998, Pediatrics.

[35]  J. Shiloach,et al.  Synthesis and immunological properties of Vi and di-O-acetyl pectin protein conjugates with adipic acid dihydrazide as the linker , 1997, Infection and immunity.

[36]  R. Schneerson,et al.  Prevention of Systemic Infections, Especially Meningitis, Caused by Haemophilus influenzae Type b: Impact on Public Health and Implications for Other Polysaccharide-Based , 1996 .

[37]  P. Anderson,et al.  The 1996 Albert Lasker Medical Research Awards. Prevention of systemic infections, especially meningitis, caused by Haemophilus influenzae type b. Impact on public health and implications for other polysaccharide-based vaccines. , 1996, JAMA.

[38]  Conjugate Vaccines.  Laboratory andPreliminary Clinical Characterization ofVi Capsular Polysaccharide-Protein , 1994 .

[39]  R. Byrd,et al.  Quantification of polysaccharide in Haemophilus influenzae type b conjugate and polysaccharide vaccines by high-performance anion-exchange chromatography with pulsed amperometric detection. , 1994, Vaccine.

[40]  R. Hepler,et al.  Carbohydrate composition analysis of bacterial polysaccharides: optimized acid hydrolysis conditions for HPAEC-PAD analysis. , 1992, Analytical biochemistry.

[41]  S. Szu,et al.  Relation between structure and immunologic properties of the Vi capsular polysaccharide , 1991, Infection and immunity.

[42]  Gary J. Nabel,et al.  New Generation Vaccines , 1990 .

[43]  S. Szu,et al.  Comparative immunogenicities of Vi polysaccharide-protein conjugates composed of cholera toxin or its B subunit as a carrier bound to high- or lower-molecular-weight Vi , 1989, Infection and immunity.

[44]  R. Schneerson,et al.  Characterization of the Salmonella paratyphi C Vi polysaccharide , 1989, Infection and immunity.

[45]  S. Szu,et al.  Application of optical properties of the Vi capsular polysaccharide for quantitation of the Vi antigen in vaccines for typhoid fever , 1988, Journal of clinical microbiology.

[46]  S. Szu,et al.  Vi capsular polysaccharide-protein conjugates for prevention of typhoid fever. Preparation, characterization, and immunogenicity in laboratory animals , 1987, The Journal of experimental medicine.

[47]  R. Schneerson,et al.  Further Studies on the Immunogenicity of Haemophilus influenzae Type b and Pneumococcal Type 6A Polysaccharide-Protein Conjugates , 1983, Infection and immunity.

[48]  D. F. Bradley,et al.  Aggregation of cationic dyes on acid polysaccharides. I. Spectrophotometric titration with acridine orange and other metachromatic dyes. , 1967, Biochimica et biophysica acta.

[49]  S. Hestrin.  The reaction of acetylcholine and other carboxylic acid derivatives with hydroxylamine, and its analytical application. , 1949, The Journal of biological chemistry.

[50]  S. Black,et al.  Safety and immunogenicity of heptavalent pneumococcal CRM 197 conjugate vaccine in infants and toddlers , 2022 .